Ahead of the 7th Annual IMPACCT: Real World Evidence, Sandy Leonard, former VP, Medical Evidence & Observational Research at AstraZeneca has taken some time
NICE has recommended interim funding on England’s NHS for AstraZeneca’s ovarian cancer drug Lynparza in the earlier stages of the disease as a maintenance treatment after an initial round o
AstraZeneca has upped its revenue expectations following a strong second quarter, saying that sales of newer drugs will offset a major patent expiry and the impact of Brexit.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
